IP Library Granted Patent US 8,906,937
Granted Patent B2
US 8,906,937 · App. 14/033,086 · Granted Dec 9, 2014

Flavivirus inhibitors and methods of their use

Inventors: Radhakrishnan Padmanabhan (Bethesda, MD); Nagarajan Pattabiraman (North Potomac, MD); Niklaus Mueller (Denver, CO); Kuppuswamy Nagarajan (Bangalore, IN)
Assignee: Georgetown University
C07D277/36C07D401/12C07D413/12C07D417/12C07D417/06C07D405/14C07D215/26C07D409/06A61K31/4709
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,906,937
App. No.
14/033,086
Granted
Dec 9, 2014
Kind
B2
Abstract

Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus serine protease inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus.

Claims (21)

1. A method of treating a Flavivirus infection in a subject, comprising administering to the subject a therapeutically effective amount of the compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 is hydroxyl;

R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from hydrogen, hydroxyl, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 heteroalkyl, substituted or unsubstituted C 2-4 alkenyl, substituted or unsubstituted C 2-4 heteroalkenyl, substituted or unsubstituted C 2-4 alkenyl, substituted or unsubstituted C 2-4 heteroalkynyl, or halogen;

A is

B is

and

R 7 is hydrogen.

2. The method of claim 1 , wherein the Flavivirus is the West Nile Virus.

3. The method of claim 1 , wherein the Flavivirus is Dengue Virus serotype DEN-1, Dengue Virus serotype DEN-2, Dengue Virus serotype DEN-3, or Dengue Virus serotype DEN-4.

4. The method of claim 1 , wherein the Flavivirus is Japanese Encephalitis Virus.

5. A compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 is hydroxyl;

R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from hydrogen, hydroxyl, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 heteroalkyl, substituted or unsubstituted C 2-4 alkenyl, substituted or unsubstituted C 2-4 heteroalkenyl, substituted or unsubstituted C 2-4 alkynyl, substituted or unsubstituted C 2-4 heteroalkynyl, or halogen;

A is

B is

and

R 7 is hydrogen.

6. The compound of claim 5 , wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen.

7. The method of claim 1 , wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 7, 2023
From: GEORGETOWN UNIVERSITY
To: NIH - DEITR
Reel/Frame 064514/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2013
From: PADMANABHAN, RADHAKRISHNAN; PATTABIRAMAN, NAGARAJAN; MUELLER, NIKLAUS; NAGARAJAN, KUPPUSWAMY
To: GEORGETOWN UNIVERSITY
Reel/Frame 031492/0141 →
Continuity (3)
Continuation 13120583
Provisional Application 61099411 · Sep 23, 2008
Related Publication 20140038962A1 · Feb 6, 2014